08:59 AM EDT, 06/03/2024 (MT Newswires) -- GSK (GSK) said Monday that longer-term results from a mid-stage study evaluating its experimental therapy, jemperli, as a first-line treatment a type of rectal cancer, showed a 100% clinical complete response rate in 42 patients, positioning it as a surgery alternative.

The safety and tolerability profile of jemperli remained largely in line with the agent's established safety profile, the UK drugmaker said.

The company said jemperli is not yet approved anywhere globally for firstline treatment of mismatch repair deficient locally advanced rectal cancer.

Price: 41.25, Change: -3.52, Percent Change: -7.86